中国药房2025，Vol.36Issue(5)：579-583,5.DOI:10.6039/j.issn.1001-0408.2025.05.13
贝莫苏拜单抗联合安罗替尼和化疗方案一线治疗广泛期小细胞肺癌的成本-效用分析
Cost-utility analysis of benmelstobart plus anlotinib and chemotherapy as first-line treatment for extensive-stage small cell lung cancer
摘要
Abstract
OBJECTIVE To evaluate the cost-utility of benmelstobart combined with anlotinib and chemotherapy as first-line treatment for extensive-stage small cell lung cancer(ES-SCLC)from the perspective of China's healthcare system.METHODS Based on the data from the ETER 701 study,a partitioned survival model was constructed with a cycle of 3 weeks to simulate the total cost,quality-adjusted life years(QALY),and incremental cost-effectiveness ratio(ICER)over 10 years for patients with ES-SCLC treated with benmelstobart plus anlotinib and chemotherapy,or chemotherapy alone.One-way sensitivity analysis and probability sensitivity analysis were performed to verify the robustness of the simulation results.The willingness-to-pay(WTP)threshold was set at 3 times the per capita gross domestic product(GDP)of China in 2023,which amounted to 268 074 yuan/QALY.RESULTS Compared with chemotherapy alone,benmelstobart combined with anlotinib and chemotherapy gained 0.438 QALY more at the cost of 403 505.55 yuan more,with an ICER of 922 031.37 yuan/QALY,which was higher than the WTP threshold set in this study.One-way sensitivity analysis showed that benmelstobart's cost and utility value of the progression-free survival state had a greater impact on the ICER value;probabilistic sensitivity analysis confirmed the robustness of the model;only when the price of benmelstobart was reduced by 75.4％,the combined regimen would be cost-effective.CONCLUSIONS The first-line treatment of ES-SCLC with benmelstobart combined with anlotinib and chemotherapy is not cost-effective from the perspective of China's healthcare system at present.关键词
贝莫苏拜单抗/安罗替尼/广泛期小细胞肺癌/分区生存模型/成本-效用分析/药物经济学Key words
benmelstobart/anlotinib/extensive-stage small cell lung cancer/partitioned survival model/cost-utility analysis/pharmacoeconomics分类
药学引用本文复制引用
冯冰,高宁,高胜男,张羽曦,张冉冉,刘国强..贝莫苏拜单抗联合安罗替尼和化疗方案一线治疗广泛期小细胞肺癌的成本-效用分析[J].中国药房,2025,36(5):579-583,5.基金项目
河北省自然科学基金项目(No.H2021206407) （No.H2021206407）
